Published by: MRG, Inc. and Fuji-Keizai USA
April 2003
No. of Pages: 162     
Price: US $995.00

TABLE OF CONTENTS
EXECUTIVE OVERVIEW

CURRENT OVERVIEW OF BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT

• THE PHARMACEUTICAL R&D PROCESS
  • Figure 1. The Drug Development Process
• OVERVIEW OF MAJOR THERAPEUTIC MARKET SEGMENTS
  • Figure 2. Distribution of companies and their products among the therapeutic classes of emerging biopharmaceutical companies.
• AUTOIMMUNE/INFLAMMATION MARKET SEGMENT
  • Figure 3. Distribution of lead drug candidates by stage of development (all market segments)
• CANCER THERAPY MARKET SEGMENT
• CNS/NEUROLOGY MARKET SEGMENT
• CELL OR GENE THERAPY MARKET SEGMENT
• INFECTIOUS DISEASE THERAPY MARKET SEGMENT
• TISSUE ENGINEERING MARKET SEGMENT
• ENABLING TECHNOLOGY MARKET SEGMENT
• HTP SCREENING MARKET SEGMENT
  

FOCUS OF BIOPHARMACEUTICAL R&D AND BUSINESS

• OVERVIEW OF EMERGING BIOPHARMACEUTICAL COMPANIES
  • Figure 4. The number of emerging biopharmaceutical companies in each major market segment
  • Figure 5. Approximate number of employees within emerging biopharmaceutical companies by market segment
  • Figure 6. Relative numbers of employees by market segment in the emerging biopharmaceutical
    industry
  • Figure 7. Distribution of emerging biopharmaceutical companies by year of incorporation
  • Table 1. The largest emerging biopharmaceutical companies profiled
• AUTOIMMUNE/INFLAMMATION MARKET SEGMENT
  • Table 2. Participants in the Autoimmune/Inflammation market segment.
  • Figure 8. Size of participants in the autoimmune/inflammation market segment in 2002
• CANCER THERAPY MARKET SEGMENT
  • Table 3. Participants in the Cancer therapy market segment
• CNS/NEUROLOGY MARKET SEGMENT
  • Table 4. Participants in the CNS/Neurology market segment
  • Figure 9. Size of participants in the CNS market segment in 2002
• CELL OR GENE THERAPY MARKET SEGMENT
  • Table 5. Participants in the Cell/Gene Therapy market segment
  • Figure 10. Size of participants in the cell/gene therapy market segment in 2002
• INFECTIOUS DISEASE THERAPY MARKET SEGMENT
  • Table 6. Participants in the Infectious Disease market segment
• TISSUE ENGINEERING MARKET SEGMENT
  • Table 7. Participants in the Tissue Engineering market segment
  • Figure 11. Size of participants in the Tissue Engineering market segment in 2002
• ENABLING TECHNOLOGY MARKET SEGMENT
  • Table 8. Participants in the Enabling Technology market segment
• HTP SCREENING MARKET SEGMENT
  • Table 9. Participants in the HTP Screening market segment
  • Figure 12. Sizes of large and small emerging technology participants in 2002
  • Figure 13. Size of participants in the HTP screening market segment in 2002
    

PRODUCT PIPELINE BY THERAPEUTIC CATEGORY

• OVERALL PRODUCT PIPELINE BY STAGE
  • Figure 14. Breakdown of lead drug candidates by stage of development
• OVERALL PRODUCT PIPELINE BY THERAPEUTIC CATEGORY
  • Figure 15. The number of lead drug candidates by disease focus
• AUTOIMMUNE AND INFLAMMATION THERAPIES
  • Figure 16. Distribution of drug candidates by stage of development at companies in the autoimmune/inflammation market segment
  • Table 10. Lead drug candidates under development in the autoimmune/inflammation market segment
• CANCER THERAPIES
  • Figure 17. Distribution of drug candidates by stage of development in the cancer market segment
  • Table 11. List of lead drug candidates under development at companies in the cancer market
    segment
• CNS/NEUROLOGY DRUGS
  • Figure 18. Distribution of drug candidates by stage of development at companies in the
  • CNS/neurology market segment
  • Table 12. List of lead drug candidates under development at companies in the CNS/neurology market segment
• CELL OR GENE THERAPY PRODUCTS
  • Table 13. List of lead drug candidates under development at cell/gene-based therapy companies
  • Figure 19. Distribution of drug candidates by stage of development at cell/gene therapy
    companies
• INFECTIOUS DISEASE THERAPIES
  • Figure 20. Distribution of drug candidates by stage of development at companies in the infectious
    disease market segment
  • Table 14. List of lead drug candidates under development at companies in the infectious disease
    market segment
    

PARTNERSHIP OPPORTUNITIES WITH EMERGING COMPANIES

• AUTOIMMUNE/INFLAMMATION SEGMENT ANALYSIS AND EVALUATION
  • Table 15. Analysis and Evaluation of the autoimmune/inflammation market segment participants
• CANCER THERAPY SEGMENT ANALYSIS AND EVALUATION
  • Table 16. Analysis and Evaluation of the cancer market segment participants
  • Table 17. Late-stage lead drug candidates in the cancer market segment
• CNS/NEUROLOGY SEGMENT ANALYSIS AND EVALUATION
  • Table 18. Analysis and Evaluation of the CNS/neurology market segment participants
  • Table 19. Late-stage lead drug candidates in the CNS/neurology market segment
• CELL/GENE THERAPY SEGMENT ANALYSIS AND EVALUATION
  • Table 20. Analysis and Evaluation of the cell/gene therapy market segment participants
• INFECTIOUS DISEASE SEGMENT ANALYSIS AND EVALUATION
  • Table 21. Analysis and Evaluation of the infectious disease market segment participants
  • Table 22. Late-stage lead drug candidates in the infectious disease market segment
• TISSUE ENGINEERING SEGMENT ANALYSIS AND EVALUATION
  • Table 23. Analysis and Evaluation of the tissue engineering market segment participants
• ENABLING TECHNOLOGY SEGMENT ANALYSIS AND EVALUATION
  • Table 24. Analysis and Evaluation of the enabling technology market segment participants
• HTP SCREENING SEGMENT ANALYSIS AND EVALUATION
  • Table 25. Analysis and Evaluation of the HTP screening market segment participants
    

COMPANY PROFILES: ACTIVITIES OF LEADING EMERGING FIRMS

• AUTOIMMUNE AND INFLAMMATION MARKET SEGMENTS
  • ChemoCentryx, Inc.
  • EluSys Therapeutics, Inc.
    
  • Epicyte
    
  • Exhale Therapeutics, Inc.
    
  • GeneEx, Inc.
    
  • Hawaii Biotech, Inc.
    
  • Santarus, Inc.
    
  • CANCER THERAPY MARKET SEGMENT
    
  • Advanced Life Sciences, Inc.
    
  • CancerVax Corp.
    
  • CEPTYR, Inc.
    
  • Conforma Therapeutics Corp.
    
  • Cyternex, Inc.
    
  • Echelon Biosciences, Inc.
    
  • EmerGen, Inc.
    
  • EXIMIAS Pharmaceutical Corporation
    
  • Favrille, Inc.
    
  • Helix Twelve Pharmaceuticals
    
  • Immunicon Corp.
    
  • Libraria, Inc.
    
  • Metabasis Therapeutics, Inc.
    
  • Raven Biotechnologies, Inc.
    
  • Receptron, Inc.
    
  • Signature BioScience, Inc.
    
  • Structural GenomiX Inc.
    
  • Syrrx, Inc.
    
  • Transave, Inc.
    
  • Triad Therapeutics, Inc.
    
  • Vaccinex, Inc.
    
• CNS/NEUROLOGY MARKET SEGMENT
  • Ceregene, Inc.
    
  • EpiCept
    
  • MIICRO Inc.
    
  • Nanomed Pharmaceuticals, Inc.
    
  • Neurogenetics, Inc.
    
  • NeuroMed Technologies, Inc.
    
  • Nyxis Neurotherapies, Inc.
    
  • Psynomics, Inc.
    
  • Rejuvenon Corp.
    
  • Sention, Inc.
    
  • Targeted Molecules Corp.
    
  • TransMolecular, Inc.
• CELL OR GENE THERAPY MARKET SEGMENT
  • Copernicus Therapeutics, Inc.
    
  • DirectGene, Inc.
    
  • Genteric
    
  • Intronn, Inc.
    
  • MaxCyte Inc.
    
  • Nephros Therapeutics, Inc.
    
  • Neuronyx, Inc.
    
  • PPL Therapeutics Inc.
    
  • REPLICor, Inc.
• INFECTIOUS DISEASE THERAPY MARKET SEGMENT
  • Anadys Pharmaceuticals, Inc.
    
  • BioSyn, Inc.
    
  • Biota, Inc.
    
  • Divergence, Inc.
    
  • First Circle Medical
    
  • Functional Genetics, Inc.
    
  • Iomai Corporation
    
  • LigoCyte Pharmaceuticals Inc.
    
  • Message Pharmaceuticals, Inc.
    
  • MithraGen Inc.
    
  • NewBiotics, Inc.
    
  • Nucleonics, Inc.
    
  • PhageTech Inc.
    
  • Quorex Pharmaceuticals, Inc.
    
  • Tao Biosciences, Inc.
• TISSUE ENGINEERING MARKET SEGMENT
  • Automated Cell Technologies, Inc.
    
  • Applied Tissue Technologies, LLC
    
  • Cellect Bio, Inc.
    
  • ReGen Biologics, Inc.
    
  • Tissue Engineering Inc.
    
  • TissueInformatics, Inc.
• ENABLING TECHNOLOGY MARKET SEGMENT
  
  • B310
    
  • Bionaut Pharmaceuticals, Inc.
    
  • BioSeek, Inc.
    
  • ChemCodes, Inc.
    
  • Genoptix
    
  • Gryphon Therapeutics, Inc.
    
  • Iris AO Inc.
    
  • IatroQuest
    
  • Lipocine, Inc.
    
  • Nanostream, Inc.
    
  • Novasite Pharmaceuticals, Inc.
    
  • Phenomix, Inc.
    
  • Picoliter Inc.
    
  • Plexxikon Inc.
    
  • Target Discovery, Inc.
    
  • U.S. Genomics
    
  • Xenogen Corporation
• HTP SCREENING MARKET SEGMENT
  
  • Aptus Pharmaceuticals, Inc.
    
  • Auilix Biopharma, Inc.
    
  • CombiMatrix Corp.
    
  • Consensus Pharmaceutics, Inc.
    
  • GenPhar, Inc.
    
  • Guava Technologies, Inc.
    
  • NimbleGen Systems, Inc.
    
  • Novasite Pharmaceuticals, Inc.
    
  • Virtual Arrays, Inc.
    

SUMMARY

APPENDICES

• APPENDIX 1 -AUTOIMMUNE AND INFLAMMATION COMPANY CONTACTS
  
• APPENDIX 2 - CANCER THERAPY COMPANY CONTACTS
  
• APPENDIX 3 - CNS/NEUROLOGY COMPANY CONTACTS
  
• APPENDIX 4 - CELL OR GENE THERAPY COMPANY CONTACTS
  
• APPENDIX 5 - INFECTIOUS DISEASE COMPANY CONTACTS
  
• APPENDIX 6 - TISSUE ENGINEERING COMPANY CONTACTS
  
• APPENDIX 7 - ENABLING TECHNOLOGY COMPANY CONTACTS
  
• APPENDIX 8 - HTP SCREENING COMPANY CONTACTS
  

Report Description
Order Form